News

---

06/17/2010
Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
Collaboration Focuses on the Discovery and Development of Multiple Antibody, Protein and Small Molecule Agents Targeting the Wnt Pathway. more

---

05/18/2010
Bayer Presents New Riociguat Phase II Data
First Phase II study in patients with pulmonary hypertension owing to interstitial lung disease meets primary objectives / First long-term extension data of Phase II study in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension show sustained improvement in exercise capacity. more

At a glance

Research expenses 2009	1,572 million EUR
In percent of division sales 2009	15%- 17%
Employees in Research & Development	approx. 5,900 (as of Dec 31, 2009)
Main research sites	Berlin and Wuppertal, Germany and Berkeley, USA
Research focus	Berlin: Diagnostic Imaging, Oncology, Women’s Healthcare Wuppertal: Cardiology, Oncology Berkeley: Applied research and life cycle management in hemophilia and Multiple Sclerosis more

Promising pipeline ensures mid- and long-term innovation

Bayer Schering Pharma concentrates its R&D activities on innovative treatment alternatives for diseases with a high unmet medical need to improve patients’ quality of life and prolong lives. The focus is on therapeutic areas with a high medical need, where more innovations are needed despite considerable progress.

We hold a leading position in many therapeutic fields: for instance in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for such a leading position in oncology.
more

About Clinical Trials

Clinical trials are used to evaluate potential treatments that have had some effect against disease in the lab, or in animal experiments. The whole point of a clinical trial is to find out if a treatment is effective.

Until sufficient results are available from many different trials it is just that, potential. Effectiveness of a treatment should never be at the expense of safety; the benefit of a treatment should always outweigh the harm and is fundamental to the conduct of all clinical trials.
more

Our research focuses mainly on therapeutic areas with significant unmet medical need. Every year, we invest between 15 and 17 percent of our total net sales in research and development.

In drug discovery we concentrate on new treatments in the fields of cancer, cardiovascular diseases and gynecological therapies, as well as new approaches to molecular imaging. To develop new drug candidates, we focus on identifying and optimizing small molecules and developing new biologics. more